Global Biosimilars Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Biosimilars market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biosimilars Segment by Company
Teva Pharmaceutical
Samsung Biologics
Novartis
Merck KgaA
Mylan
Roche
Eli Lilly
Pfizer
Gan & Lee Pharmaceuticals
Biogen
Amgen
Stada Arzneimittel AG
Probiomed
JCR Pharmaceuticals
Gedeon Richter
Fresenius Kabi AG
Dr. Reddy's Laboratories
Coherus Bioscience
Chong Kun Dang
Celltrion
Boehringer Ingelheim
Biocon
Biocad
Apotex
Biosimilars Segment by Type
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Biosimilars Segment by Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Biosimilars market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biosimilars Segment by Company
Teva Pharmaceutical
Samsung Biologics
Novartis
Merck KgaA
Mylan
Roche
Eli Lilly
Pfizer
Gan & Lee Pharmaceuticals
Biogen
Amgen
Stada Arzneimittel AG
Probiomed
JCR Pharmaceuticals
Gedeon Richter
Fresenius Kabi AG
Dr. Reddy's Laboratories
Coherus Bioscience
Chong Kun Dang
Celltrion
Boehringer Ingelheim
Biocon
Biocad
Apotex
Biosimilars Segment by Type
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Biosimilars Segment by Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
218 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Biosimilars Market by Type
- 1.2.1 Global Biosimilars Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
- 1.2.3 Recombinant Glycosylated Proteins
- 1.3 Biosimilars Market by Application
- 1.3.1 Global Biosimilars Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Oncology
- 1.3.3 Blood Disorders
- 1.3.4 Growth Hormonal Deficiency
- 1.3.5 Chronic and Autoimmune Disorders
- 1.3.6 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Biosimilars Market Dynamics
- 2.1 Biosimilars Industry Trends
- 2.2 Biosimilars Industry Drivers
- 2.3 Biosimilars Industry Opportunities and Challenges
- 2.4 Biosimilars Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Biosimilars Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Biosimilars Revenue by Region
- 3.2.1 Global Biosimilars Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Biosimilars Revenue by Region (2020-2025)
- 3.2.3 Global Biosimilars Revenue by Region (2026-2031)
- 3.2.4 Global Biosimilars Revenue Market Share by Region (2020-2031)
- 3.3 Global Biosimilars Sales Estimates and Forecasts 2020-2031
- 3.4 Global Biosimilars Sales by Region
- 3.4.1 Global Biosimilars Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Biosimilars Sales by Region (2020-2025)
- 3.4.3 Global Biosimilars Sales by Region (2026-2031)
- 3.4.4 Global Biosimilars Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Biosimilars Revenue by Manufacturers
- 4.1.1 Global Biosimilars Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Biosimilars Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Biosimilars Sales by Manufacturers
- 4.2.1 Global Biosimilars Sales by Manufacturers (2020-2025)
- 4.2.2 Global Biosimilars Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Biosimilars Sales Price by Manufacturers (2020-2025)
- 4.4 Global Biosimilars Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Biosimilars Manufacturers, Product Type & Application
- 4.7 Global Biosimilars Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Biosimilars Market CR5 and HHI
- 4.8.2 2024 Biosimilars Tier 1, Tier 2, and Tier 3
- 5 Biosimilars Market by Type
- 5.1 Global Biosimilars Revenue by Type
- 5.1.1 Global Biosimilars Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Biosimilars Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Biosimilars Revenue Market Share by Type (2020-2031)
- 5.2 Global Biosimilars Sales by Type
- 5.2.1 Global Biosimilars Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Biosimilars Sales by Type (2020-2031) & (k units)
- 5.2.3 Global Biosimilars Sales Market Share by Type (2020-2031)
- 5.3 Global Biosimilars Price by Type
- 6 Biosimilars Market by Application
- 6.1 Global Biosimilars Revenue by Application
- 6.1.1 Global Biosimilars Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Biosimilars Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Biosimilars Revenue Market Share by Application (2020-2031)
- 6.2 Global Biosimilars Sales by Application
- 6.2.1 Global Biosimilars Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Biosimilars Sales by Application (2020-2031) & (k units)
- 6.2.3 Global Biosimilars Sales Market Share by Application (2020-2031)
- 6.3 Global Biosimilars Price by Application
- 7 Company Profiles
- 7.1 Teva Pharmaceutical
- 7.1.1 Teva Pharmaceutical Comapny Information
- 7.1.2 Teva Pharmaceutical Business Overview
- 7.1.3 Teva Pharmaceutical Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Teva Pharmaceutical Biosimilars Product Portfolio
- 7.1.5 Teva Pharmaceutical Recent Developments
- 7.2 Samsung Biologics
- 7.2.1 Samsung Biologics Comapny Information
- 7.2.2 Samsung Biologics Business Overview
- 7.2.3 Samsung Biologics Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Samsung Biologics Biosimilars Product Portfolio
- 7.2.5 Samsung Biologics Recent Developments
- 7.3 Novartis
- 7.3.1 Novartis Comapny Information
- 7.3.2 Novartis Business Overview
- 7.3.3 Novartis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Novartis Biosimilars Product Portfolio
- 7.3.5 Novartis Recent Developments
- 7.4 Merck KgaA
- 7.4.1 Merck KgaA Comapny Information
- 7.4.2 Merck KgaA Business Overview
- 7.4.3 Merck KgaA Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Merck KgaA Biosimilars Product Portfolio
- 7.4.5 Merck KgaA Recent Developments
- 7.5 Mylan
- 7.5.1 Mylan Comapny Information
- 7.5.2 Mylan Business Overview
- 7.5.3 Mylan Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Mylan Biosimilars Product Portfolio
- 7.5.5 Mylan Recent Developments
- 7.6 Roche
- 7.6.1 Roche Comapny Information
- 7.6.2 Roche Business Overview
- 7.6.3 Roche Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Roche Biosimilars Product Portfolio
- 7.6.5 Roche Recent Developments
- 7.7 Eli Lilly
- 7.7.1 Eli Lilly Comapny Information
- 7.7.2 Eli Lilly Business Overview
- 7.7.3 Eli Lilly Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Eli Lilly Biosimilars Product Portfolio
- 7.7.5 Eli Lilly Recent Developments
- 7.8 Pfizer
- 7.8.1 Pfizer Comapny Information
- 7.8.2 Pfizer Business Overview
- 7.8.3 Pfizer Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Pfizer Biosimilars Product Portfolio
- 7.8.5 Pfizer Recent Developments
- 7.9 Gan & Lee Pharmaceuticals
- 7.9.1 Gan & Lee Pharmaceuticals Comapny Information
- 7.9.2 Gan & Lee Pharmaceuticals Business Overview
- 7.9.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
- 7.9.5 Gan & Lee Pharmaceuticals Recent Developments
- 7.10 Biogen
- 7.10.1 Biogen Comapny Information
- 7.10.2 Biogen Business Overview
- 7.10.3 Biogen Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Biogen Biosimilars Product Portfolio
- 7.10.5 Biogen Recent Developments
- 7.11 Amgen
- 7.11.1 Amgen Comapny Information
- 7.11.2 Amgen Business Overview
- 7.11.3 Amgen Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 Amgen Biosimilars Product Portfolio
- 7.11.5 Amgen Recent Developments
- 7.12 Stada Arzneimittel AG
- 7.12.1 Stada Arzneimittel AG Comapny Information
- 7.12.2 Stada Arzneimittel AG Business Overview
- 7.12.3 Stada Arzneimittel AG Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Stada Arzneimittel AG Biosimilars Product Portfolio
- 7.12.5 Stada Arzneimittel AG Recent Developments
- 7.13 Probiomed
- 7.13.1 Probiomed Comapny Information
- 7.13.2 Probiomed Business Overview
- 7.13.3 Probiomed Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Probiomed Biosimilars Product Portfolio
- 7.13.5 Probiomed Recent Developments
- 7.14 JCR Pharmaceuticals
- 7.14.1 JCR Pharmaceuticals Comapny Information
- 7.14.2 JCR Pharmaceuticals Business Overview
- 7.14.3 JCR Pharmaceuticals Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.14.4 JCR Pharmaceuticals Biosimilars Product Portfolio
- 7.14.5 JCR Pharmaceuticals Recent Developments
- 7.15 Gedeon Richter
- 7.15.1 Gedeon Richter Comapny Information
- 7.15.2 Gedeon Richter Business Overview
- 7.15.3 Gedeon Richter Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.15.4 Gedeon Richter Biosimilars Product Portfolio
- 7.15.5 Gedeon Richter Recent Developments
- 7.16 Fresenius Kabi AG
- 7.16.1 Fresenius Kabi AG Comapny Information
- 7.16.2 Fresenius Kabi AG Business Overview
- 7.16.3 Fresenius Kabi AG Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.16.4 Fresenius Kabi AG Biosimilars Product Portfolio
- 7.16.5 Fresenius Kabi AG Recent Developments
- 7.17 Dr. Reddy's Laboratories
- 7.17.1 Dr. Reddy's Laboratories Comapny Information
- 7.17.2 Dr. Reddy's Laboratories Business Overview
- 7.17.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.17.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
- 7.17.5 Dr. Reddy's Laboratories Recent Developments
- 7.18 Coherus Bioscience
- 7.18.1 Coherus Bioscience Comapny Information
- 7.18.2 Coherus Bioscience Business Overview
- 7.18.3 Coherus Bioscience Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.18.4 Coherus Bioscience Biosimilars Product Portfolio
- 7.18.5 Coherus Bioscience Recent Developments
- 7.19 Chong Kun Dang
- 7.19.1 Chong Kun Dang Comapny Information
- 7.19.2 Chong Kun Dang Business Overview
- 7.19.3 Chong Kun Dang Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.19.4 Chong Kun Dang Biosimilars Product Portfolio
- 7.19.5 Chong Kun Dang Recent Developments
- 7.20 Celltrion
- 7.20.1 Celltrion Comapny Information
- 7.20.2 Celltrion Business Overview
- 7.20.3 Celltrion Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.20.4 Celltrion Biosimilars Product Portfolio
- 7.20.5 Celltrion Recent Developments
- 7.21 Boehringer Ingelheim
- 7.21.1 Boehringer Ingelheim Comapny Information
- 7.21.2 Boehringer Ingelheim Business Overview
- 7.21.3 Boehringer Ingelheim Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.21.4 Boehringer Ingelheim Biosimilars Product Portfolio
- 7.21.5 Boehringer Ingelheim Recent Developments
- 7.22 Biocon
- 7.22.1 Biocon Comapny Information
- 7.22.2 Biocon Business Overview
- 7.22.3 Biocon Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.22.4 Biocon Biosimilars Product Portfolio
- 7.22.5 Biocon Recent Developments
- 7.23 Biocad
- 7.23.1 Biocad Comapny Information
- 7.23.2 Biocad Business Overview
- 7.23.3 Biocad Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.23.4 Biocad Biosimilars Product Portfolio
- 7.23.5 Biocad Recent Developments
- 7.24 Apotex
- 7.24.1 Apotex Comapny Information
- 7.24.2 Apotex Business Overview
- 7.24.3 Apotex Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.24.4 Apotex Biosimilars Product Portfolio
- 7.24.5 Apotex Recent Developments
- 8 North America
- 8.1 North America Biosimilars Market Size by Type
- 8.1.1 North America Biosimilars Revenue by Type (2020-2031)
- 8.1.2 North America Biosimilars Sales by Type (2020-2031)
- 8.1.3 North America Biosimilars Price by Type (2020-2031)
- 8.2 North America Biosimilars Market Size by Application
- 8.2.1 North America Biosimilars Revenue by Application (2020-2031)
- 8.2.2 North America Biosimilars Sales by Application (2020-2031)
- 8.2.3 North America Biosimilars Price by Application (2020-2031)
- 8.3 North America Biosimilars Market Size by Country
- 8.3.1 North America Biosimilars Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Biosimilars Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Biosimilars Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 9 Europe
- 9.1 Europe Biosimilars Market Size by Type
- 9.1.1 Europe Biosimilars Revenue by Type (2020-2031)
- 9.1.2 Europe Biosimilars Sales by Type (2020-2031)
- 9.1.3 Europe Biosimilars Price by Type (2020-2031)
- 9.2 Europe Biosimilars Market Size by Application
- 9.2.1 Europe Biosimilars Revenue by Application (2020-2031)
- 9.2.2 Europe Biosimilars Sales by Application (2020-2031)
- 9.2.3 Europe Biosimilars Price by Application (2020-2031)
- 9.3 Europe Biosimilars Market Size by Country
- 9.3.1 Europe Biosimilars Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Biosimilars Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Biosimilars Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
- 9.3.9 Nordic Countries
- 10 China
- 10.1 China Biosimilars Market Size by Type
- 10.1.1 China Biosimilars Revenue by Type (2020-2031)
- 10.1.2 China Biosimilars Sales by Type (2020-2031)
- 10.1.3 China Biosimilars Price by Type (2020-2031)
- 10.2 China Biosimilars Market Size by Application
- 10.2.1 China Biosimilars Revenue by Application (2020-2031)
- 10.2.2 China Biosimilars Sales by Application (2020-2031)
- 10.2.3 China Biosimilars Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Biosimilars Market Size by Type
- 11.1.1 Asia Biosimilars Revenue by Type (2020-2031)
- 11.1.2 Asia Biosimilars Sales by Type (2020-2031)
- 11.1.3 Asia Biosimilars Price by Type (2020-2031)
- 11.2 Asia Biosimilars Market Size by Application
- 11.2.1 Asia Biosimilars Revenue by Application (2020-2031)
- 11.2.2 Asia Biosimilars Sales by Application (2020-2031)
- 11.2.3 Asia Biosimilars Price by Application (2020-2031)
- 11.3 Asia Biosimilars Market Size by Country
- 11.3.1 Asia Biosimilars Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Biosimilars Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Biosimilars Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Biosimilars Market Size by Type
- 12.1.1 SAMEA Biosimilars Revenue by Type (2020-2031)
- 12.1.2 SAMEA Biosimilars Sales by Type (2020-2031)
- 12.1.3 SAMEA Biosimilars Price by Type (2020-2031)
- 12.2 SAMEA Biosimilars Market Size by Application
- 12.2.1 SAMEA Biosimilars Revenue by Application (2020-2031)
- 12.2.2 SAMEA Biosimilars Sales by Application (2020-2031)
- 12.2.3 SAMEA Biosimilars Price by Application (2020-2031)
- 12.3 SAMEA Biosimilars Market Size by Country
- 12.3.1 SAMEA Biosimilars Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Biosimilars Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Biosimilars Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Biosimilars Value Chain Analysis
- 13.1.1 Biosimilars Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Biosimilars Production Mode & Process
- 13.2 Biosimilars Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Biosimilars Distributors
- 13.2.3 Biosimilars Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

